2018 American Transplant Congress
Burden of Primary CMV Infections Remains High Despite Six Months Valganciclovir Prophylaxis in High-Risk Kidney Transplant Recipients
A. Prophylaxis has mostly replaced preemptive therapy in CMV seronegative recipients of kidneys from seropositive donors (D+/R-). Primary infections occur commonly even after six months…2018 American Transplant Congress
CMV-Specific CD8+ T-Cell Immune Competence Score as Predictor of Outcome for CMV Infection after Transplantation
Introduction: Control of cytomegalovirus (CMV) infection after solid organ transplantation (SOT) requires a functional immune system. We assessed the utility of a flow cytometric assay…2018 American Transplant Congress
Significant Anti-CMV/BKV Effect of a Modern Everolimus-Based Regimen Comparted to a Standard Tacrolimus-MPA Regimen in De Novo Kidney Transplant Recipients: ATHENA 12 Months Data on Infections
1Athena Study Group, Germany; 2Athena Study Group, France; 3Novartis, Pharma, Germany.
The ATHENA trial was designed to compare everolimus [EVR] in combination with tacrolimus [TAC] or cyclosporine A [CyA] vs. a standard regimen of mycophenolic acid…2018 American Transplant Congress
Cause of ESRD is Not Associated with Risk of Post-Transplant CMV Infection
University of Wisconsin Madison, Madison, WI.
Purpose: Cytomegalovirus (CMV) infection is commonly encountered following kidney transplantation and is associated with patient morbidity and mortality. While preventative pharmacotherapy is used to prevent…2018 American Transplant Congress
Evaluation of a Change in CMV Prevention Strategy Following Pediatric SOT
Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Optimal cytomegalovirus(CMV) prevention strategy following solid organ transplantation(SOT) is uncertain. We report on CMV disease with implementation of prophylaxis-based prevention with intensive monitoring.We retrospectively evaluated…2018 American Transplant Congress
CMV-Specific Cell-Mediated Immunity after Valgancyclovir Prophylaxis Predicts Late Onset CMV Infection in Kidney Transplant Patients
Background: There is currently no means to predict late-onset CMV infection after a long course of post-transplant Valgancyclovir prophylaxis therapy and its development still negatively…2018 American Transplant Congress
Relation between Seroprevalence of Cytomegalovirus and Graft Survival in Japanese Kidney Transplant Recipients: The Japan Academic Consortium of Kidney Transplantation Study
BackgroundCytomegalovirus (CMV) infection is one of major causes of morbidity in kidney transplant recipients (KTRs). However, the current prevalence of CMV in KTRs and the…2018 American Transplant Congress
Efficacy of Two Valganciclovir Dosing Strategies in Intermediate and High-Risk Liver Transplant Recipients
Purpose: There is interest in reduced dosing and duration of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant (LT) recipients to minimize side effects…2017 American Transplant Congress
Prospective Randomized Trial for Predicting CMV Infection According to Baseline CMV-Specific T-Cell Immunity in Kidney Transplant Patients.
Background: Despite the use of either anti-viral prophylaxis (PF) or preemptive (PE) therapy given based on donor/recipient IgG-serostatus, Cytomegalovirus (CMV) reactivation persists after kidney transplantation…2017 American Transplant Congress
Utility of “High-Dose” Ganciclovir in High Viral Load CMV Infection in Transplant Recipients.
Background: High-dose ganciclovir (GCV) is often used for treatment of high viral load CMV, but few data exist on virologic outcomes and risk of neutropenia.…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 33
- Next Page »